Evidence map›Paper›PMID 30774408›Full record

ArticleClinical and experimental gastroenterology2019

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease - associations with disease phenotype, treatment, and outcome.

Christine Olbjørn, Milada Cvancarova Småstuen, Espen Thiis-Evensen, Britt Nakstad, Morten Harald Vatn, Jørgen Jahnsen, Petr Ricanek, Simen Vatn, Aina E F Moen, Tone M Tannæs and 10 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and experimental gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 5 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 5 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Gut microbiota in treatment-naïve active Crohn's disease compared to those in remission: Divergent trends in mucosal versus fecal bacterial community.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Article
  8. Article
  9. Inflammatory Bowel Disease in Children and Young People Living With Overweight or Obesity: A Critical Narrative Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Dysbiosis-associated gut bacteriumMicrobiology spectrum · 2025
    Article
  17. Observational
  18. The Role of Vitamin D in Gastrointestinal Homeostasis and Gut Inflammation.International journal of molecular sciences · 2025
    Review
  19. Comprehensive antibiotic resistome comparison ofCurrent research in microbial sciences · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 4 countries.

Christine OlbjørnDepartment of Pediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway, chrisolb@gmail.com.
Milada Cvancarova SmåstuenFaculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
Espen Thiis-EvensenDepartment of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Britt NakstadDepartment of Pediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway, chrisolb@gmail.com.
Morten Harald VatnDepartment of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, and University of Oslo, Oslo, Norway.
Jørgen JahnsenInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway, chrisolb@gmail.com.
Petr RicanekInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway, chrisolb@gmail.com.
Simen VatnInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway, chrisolb@gmail.com.
Aina E F MoenDepartment of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, and University of Oslo, Oslo, Norway.
Tone M TannæsDepartment of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, and University of Oslo, Oslo, Norway.
Jonas C LindstrømInstitute of Clinical Medicine, University of Oslo, Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
Johan D SöderholmDepartment of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Jonas HalfvarsonDepartment of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Fernando GomollónDigestive Diseases Unit, IIS Aragón, Zaragoza, Spain.
Christina CasénGenetic-Analysis AS, Oslo, Norway.
Magdalena K KarlssonGenetic-Analysis AS, Oslo, Norway.
Rahul KallaGastrointestinal Unit, Centre for Genomics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Alex T AdamsGastrointestinal Unit, Centre for Genomics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Jack SatsangiGastrointestinal Unit, Centre for Genomics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
Gøri PerminowDepartment of Pediatrics, Oslo University Hospital, Ullevål, Oslo, Norway.
University of Oslo · NOGenetic Analysis (Norway) · NOLinköping University · SEOslo University Hospital · NOUniversity of Oxford · GBEdinburgh Genomics · GBInstituto de Investigación Sanitaria Aragón · ESOsloMet – Oslo Metropolitan University · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImbalance in the microbiota, dysbiosis, has been identified in inflammatory bowel disease (IBD). We explored the fecal microbiota in pediatric patients with treatment-naïve IBD, non-IBD patients with gastrointestinal symptoms and healthy children, its relation to IBD subgroups, and treatment outcomes. PATIENTS AND

methodsFecal samples were collected from 235 children below 18 years of age. Eighty children had Crohn's disease (CD), 27 ulcerative colitis (UC), 3 IBD unclassified, 50 were non-IBD symptomatic patients, and 75 were healthy. The bacterial abundance of 54 predefined DNA markers was measured with a 16S rRNA DNA-based test using GA-Map

resultsBacterial abundance was similarly reduced in IBD and non-IBD patients in 51 of 54 markers compared to healthy patients (

conclusionFecal microbiota profiles differentiated IBD and non-IBD symptomatic children from healthy children, but displayed similar dysbiosis in IBD and non-IBD symptomatic patients. Pretreatment fecal microbiota profiles may be of prognostic value and aid in treatment individualization in pediatric IBD as severe dysbiosis was associated with an extensive, complicated phenotype, biologic therapy, and nonmucosal healing. The dysbiosis persisted after therapy, regardless of treatments and mucosal healing.

Indexed as

biologic therapyCrohn’s diseasedysbiosisFaecalibacterium prausnitziiProteobacteriaulcerative colitis

Identifiers

PMID30774408
PMCPMC6362922
OpenAlexW2913282449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.